Qlucore (QCORE) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
24 Sep, 2025Executive summary
Net sales for the first quarter were SEK 811k, a 52% decrease year-over-year due to a major customer not renewing licenses after internal cost cuts and reorganization.
Operating result (EBIT) improved to SEK -6,552k from SEK -7,620k year-over-year.
Net result for the period was SEK -6,619k, compared to SEK -7,529k in the prior year.
A rights issue post-period injected SEK 14.5 million in liquidity, with a significant dilution effect.
Focus during the period was on securing financing, expanding market presence, and implementing a cost-saving program exceeding 25%.
Financial highlights
Net sales dropped 51.6% year-over-year to SEK 811k.
Operating result (EBIT) margin improved to -193.6% from -278.3% year-over-year.
EBITDA for the quarter was SEK -4,382k, up from SEK -6,470k last year.
Cash flow from operating activities was SEK 1,926k, down from SEK 2,480k.
Net cash flow was SEK 774k, compared to SEK -209k last year.
Outlook and guidance
No formal market outlook or business performance forecast is provided.
Cost-saving measures, including personnel reductions, are expected to take full effect in November.
The liquidity injection from the rights issue is expected to ensure stable operations.
Latest events from Qlucore
- Sales fell sharply and losses persisted, but cash flow improved after a rights issue.QCORE
Q3 202626 Feb 2026 - Q2 saw lower sales, major write-offs, cost cuts, and improved liquidity from a rights issue.QCORE
Q2 202627 Nov 2025 - Sales fell sharply year-over-year, but Q4 losses narrowed and first Diagnostics sale completed.QCORE
Q4 202518 Jun 2025 - Regulatory milestones achieved, but sales and profitability declined significantly year-over-year.QCORE
Q2 202513 Jun 2025 - Qlucore's Q1 loss widened as sales fell, but EU funding boosted cash flow and supported diagnostics R&D.QCORE
Q1 202513 Jun 2025 - Sales fell sharply and liquidity is critical despite Diagnostics BCP-ALL 1.0 launch.QCORE
Q3 20255 Jun 2025